{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abrocitinib+tablet", "query": { "intervention": "Abrocitinib tablet" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abrocitinib+tablet&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T21:46:49.595Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06597396", "title": "Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-COVID Condition", "Fatigue Symptom" ], "interventions": [ { "name": "Abrocitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 46, "start_date": "2024-12-27", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06597396" }, { "nct_id": "NCT03720470", "title": "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis", "Dermatitis, Atopic", "Eczema", "Skin Diseases", "Skin Diseases, Genetic", "Genetic Diseases, Inborn", "Skin Diseases, Eczematous", "Hypersensitivity", "Hypersensitivity, Immediate", "Immune System Diseases" ], "interventions": [ { "name": "PF-04965842 100 mg", "type": "DRUG" }, { "name": "PF-04965842 200 mg", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" }, { "name": "Injectable Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 838, "start_date": "2018-10-29", "completion_date": "2020-03-06", "has_results": true, "last_update_posted_date": "2021-01-19", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03720470" }, { "nct_id": "NCT05743244", "title": "Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Abrocitinib 200 MG Oral Tablet", "type": "DRUG" }, { "name": "Ritlecitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "12 Years to 35 Years" }, "enrollment_count": 78, "start_date": "2023-10-19", "completion_date": "2027-10-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 23, "location_summary": "Orange, California • Palo Alto, California • San Francisco, California + 20 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743244" }, { "nct_id": "NCT03575871", "title": "Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "PF-04965842 100 mg", "type": "DRUG" }, { "name": "PF-04965842 200 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 391, "start_date": "2018-06-29", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 28, "location_summary": "Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575871" }, { "nct_id": "NCT03662516", "title": "A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Females" ], "interventions": [ { "name": "PF-04965842", "type": "DRUG" }, { "name": "Ethinyl estradiol (EE) and levonorgestrel (LN)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 17, "start_date": "2018-09-26", "completion_date": "2019-01-19", "has_results": false, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03662516" }, { "nct_id": "NCT04903093", "title": "A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Abrocitinib tablet", "type": "DRUG" }, { "name": "Abrocitinib Suspension F1", "type": "DRUG" }, { "name": "Abrocitinib Suspension F2", "type": "DRUG" }, { "name": "Abrocitinib Suspension F3", "type": "DRUG" }, { "name": "Abrocitinib Suspension F4", "type": "DRUG" }, { "name": "Abrocitinib Suspension F5", "type": "DRUG" }, { "name": "Abrocitinib Suspension F6", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 19, "start_date": "2021-06-04", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2024-11-14", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04903093" }, { "nct_id": "NCT05038982", "title": "Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prurigo Nodularis", "Pruritus", "Chronic Pruritus", "Chronic Prurigo", "Skin Diseases" ], "interventions": [ { "name": "Abrocitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2021-09-09", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038982" }, { "nct_id": "NCT03627767", "title": "Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis", "Dermatitis, Atopic", "Eczema", "Skin Diseases", "Skin Diseases, Genetic", "Genetic Diseases, Inborn", "Skin Diseases, Eczematous", "Hypersensitivity", "Hypersensitivity, Immediate", "Immune System Diseases" ], "interventions": [ { "name": "PF-04965842 100 mg", "type": "DRUG" }, { "name": "PF-04965842 200 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1235, "start_date": "2018-06-11", "completion_date": "2020-10-07", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Fremont, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03627767" }, { "nct_id": "NCT03422822", "title": "Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Abrocitinib 100 mg", "type": "DRUG" }, { "name": "Abrocitinib 200 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 3166, "start_date": "2018-03-08", "completion_date": "2025-12-22", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 156, "location_summary": "Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03422822" }, { "nct_id": "NCT04345367", "title": "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Abrocitinib 200 mg", "type": "DRUG" }, { "name": "Dupilumab 300 mg", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 727, "start_date": "2020-06-11", "completion_date": "2021-07-13", "has_results": true, "last_update_posted_date": "2022-07-08", "last_synced_at": "2026-09-07T21:46:49.595Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04345367" } ] }